Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

NCT07148050 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT07148050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07148050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 22, 2025
Completion date
April 22, 2044
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

embryonal sarcoma of liver, hepatoblastoma, hepatocellular carcinoma, liposarcoma, liver cell carcinoma, malignant rhabdoid tumor, rhabdomyosarcoma, solid tumor (excluding cns), wilms tumor, yolk sac tumor